HFA-ICOS Risk Stratification for Trastuzumab-Related Cardiac Dysfunction in HER2- Positive Breast Cancer: A Cohort Study from Saudi Arabia
This retrospective cohort study of 369 Saudi Arabian patients demonstrates that the HFA-ICOS risk stratification tool effectively predicts trastuzumab-related cardiac dysfunction, with incidence rates rising sharply from 5.2% in low-risk to 58.3% in very high-risk patients, while also identifying diabetes and hypertension as significant comorbid risk factors.